Trial Information
Summary: A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Status: No longer recruiting
Protocol Number: MA19547
Sponsor: Hoffmann-La Roche
Company Division: Pharmaceutical
Official Scientific Title: Randomized, open-label, multi-center study to investigate patient preference on dosing in women with postmenopausal osteoporosis treated with once monthly ibandronate and once weekly risedronate. A six month, two-sequence and two-period crossover study.
Brief Summary: This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12 weeks; they will then cross over to receive the alternative treatment for a further 12 weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals. Target sample size is 356.
Study Phase: IV
Study Design / Study Details:
- Purpose: Treatment
- Allocation: Randomized
- Masking: Open Label
- Control: Active
- Assignment: Crossover
- Endpoints: Safety/Efficacy
Study Type:
Interventional
Condition: Post-Menopausal Osteoporosis
Intervention Type: Drug
Intervention Name: ibandronate [Bonviva/Boniva]
Primary Outcome: 1. Proportion of patients preferring monthly dosing with Bonviva over weekly dosing with risedronate Time frame: 6 months
Key Secondary Outcomes: 1. Convenience of monthly Bonviva over weekly risedronate Time frame: 6 months
2. Change in serum CTX Time frame: 12 weeks/3 months
3. Upper gastrointestinal symptoms Time frame: 12 weeks/3 months
4. AEs and laboratory parameters Time frame: Throughout study
Inclusion Criteria:
- ambulatory women with post-menopausal osteoporosis;
- patients who are bisphosphonate-naive, or who have previously received oral daily or i.v. bisphosphonate therapy (fulfilling certain criteria detailed in the protocol).
Exclusion Criteria:
- malignant disease diagnosed within previous 10 years (except for successfully resected basal cell cancer;) breast cancer within previous 20 years;
- inability to stand or sit upright for at least 60 minutes;
- disease/disorder/treatment with drugs known to influence bone metabolism.
Gender: Females
Age Limits: Min: 55 Years Max: 80 Years
Accepts Healthy Volunteers: No
Anticipated Start Date: May, 2006
Trial Registration Date: 09/18/2006
Date Last Updated: 08/18/2008
Link To Trial Results
|
Contact:
Research Site:
Located In:
Mesa, AZ 85206
Telephone: 973-235-5000 or 800-526-6367
|
|

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: August 20, 2008 at 2:21:18 PM